Metsera (NASDAQ:MTSR) Sets New 52-Week High - What's Next?

Metsera Inc. (NASDAQ:MTSR - Get Free Report) shares reached a new 52-week high during mid-day trading on Friday . The stock traded as high as $38.02 and last traded at $37.74, with a volume of 228794 shares trading hands. The stock had previously closed at $36.41.

Analysts Set New Price Targets

MTSR has been the subject of a number of analyst reports. Wells Fargo & Company initiated coverage on Metsera in a research report on Friday, June 20th. They set an "overweight" rating and a $65.00 price objective for the company. Guggenheim boosted their price objective on Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Metsera has a consensus rating of "Buy" and a consensus price target of $55.00.

Metsera Trading Up 6.3%

The firm's 50-day moving average is $28.27.

Metsera (NASDAQ:MTSR - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($1.03) earnings per share (EPS) for the quarter.

Institutional Trading of Metsera

Several hedge funds have recently modified their holdings of MTSR. Exchange Traded Concepts LLC bought a new stake in shares of Metsera during the second quarter worth $1,153,000. Goldman Sachs Group Inc. bought a new position in Metsera in the first quarter valued at $568,000. Rhumbline Advisers bought a new stake in shares of Metsera during the 1st quarter worth approximately $520,000. Strs Ohio acquired a new position in Metsera during the first quarter worth approximately $76,000. Finally, Siren L.L.C. bought a new stake in Metsera in the first quarter valued at approximately $4,083,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.